Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-01-18
2011-01-18
Jiang, Dong (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387900, C530S388100, C530S809000, C530S350000
Reexamination Certificate
active
07871616
ABSTRACT:
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
REFERENCES:
patent: 3654090 (1972-04-01), Hermanus et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 5488032 (1996-01-01), Dower et al.
patent: 5723299 (1998-03-01), Bell et al.
patent: 5789192 (1998-08-01), Moore et al.
patent: 5843725 (1998-12-01), Sledziewski et al.
patent: 5945511 (1999-08-01), Lok et al.
patent: 5965704 (1999-10-01), Lok et al.
patent: 5985614 (1999-11-01), Rosen et al.
patent: 6020163 (2000-02-01), Conklin
patent: 6274710 (2001-08-01), Dumoutier et al.
patent: 6486301 (2002-11-01), Ebner et al.
patent: 6576743 (2003-06-01), Conklin et al.
patent: 6610286 (2003-08-01), Thompson et al.
patent: 6875845 (2005-04-01), Presnell et al.
patent: 6897292 (2005-05-01), Presnell et al.
patent: 7537761 (2009-05-01), Xu et al.
patent: 2002/0042366 (2002-04-01), Thompson et al.
patent: 2002/0085992 (2002-07-01), Chandrasekher et al.
patent: 2003/0022827 (2003-01-01), Weiss et al.
patent: 2003/0157096 (2003-08-01), Kindsvogel et al.
patent: 2004/0209330 (2004-10-01), Ku et al.
patent: 2005/0136004 (2005-06-01), Ku et al.
patent: WO 02/072607 (1902-09-01), None
patent: WO 94/13801 (1994-06-01), None
patent: WO 98/02542 (1998-01-01), None
patent: WO 98/37193 (1998-08-01), None
patent: WO 99/03982 (1999-01-01), None
patent: WO 99/07740 (1999-02-01), None
patent: WO 99/07848 (1999-02-01), None
patent: WO 99/27103 (1999-06-01), None
patent: WO 99/37772 (1999-07-01), None
patent: WO 99/46281 (1999-09-01), None
patent: WO 99/46379 (1999-09-01), None
patent: WO 99/61630 (1999-12-01), None
patent: WO 00/24758 (2000-05-01), None
patent: WO 00/39161 (2000-07-01), None
patent: WO 00/42189 (2000-07-01), None
patent: WO 00/65027 (2000-11-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 00/73457 (2000-12-01), None
patent: WO 00/77037 (2000-12-01), None
patent: WO 01/04304 (2001-01-01), None
patent: WO 01/12672 (2001-02-01), None
patent: WO 01/16318 (2001-03-01), None
patent: WO 01/36467 (2001-05-01), None
patent: WO 01/40467 (2001-06-01), None
patent: WO 01/46232 (2001-06-01), None
patent: WO 01/46261 (2001-06-01), None
patent: WO 01/46422 (2001-06-01), None
patent: WO 01/98342 (2001-12-01), None
patent: WO 02/20569 (2002-03-01), None
patent: WO 02/24912 (2002-03-01), None
patent: WO 02/058724 (2002-08-01), None
patent: WO 02/066647 (2002-08-01), None
patent: WO 02/068476 (2002-09-01), None
patent: WO 02/070001 (2002-09-01), None
patent: WO 02/077174 (2002-10-01), None
patent: WO 03/035096 (2003-05-01), None
patent: WO 03/039444 (2003-05-01), None
patent: WO 03/051384 (2003-06-01), None
patent: WO 2004/085475 (2004-10-01), None
Apparailly et al., “Interleukin-22 gene transfer in experimental model of arthritis,”American College of Rheumatology, Abstract Supplement, S671, Abstract 1755, 2003.
Asadullah et al., “Analysis of Cytokine Expression in Dermatology,”Arch. Dermatol. 138(9): 1189-1196, Sep. 2002.
Asadullah et al., “Interleukin-10 Therapy—Review of a New Approach,”Pharmacol. Rev. 55(2): 241-269, 2003.
Baumann and Gauldie, “The acute phase response,”Immunology Today15(2): 74-80, 1994.
Blumberg at al., “Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function,”Cell104: 9-19, Jan. 2001.
Bork et al., “Go hunting in sequence databases but watch out for the traps,”TIG12(10): 425-427, 1996.
Bork et al., “Predicting functions from protein sequences—where are the bottlenecks?”Nature Genetics18: 313-318, 1998.
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,”Genome Research10 : 398-400, 2000.
Cameron et al., “Cytokines and Chemokines-Their Receptors and Their Genes: An Overview,” Ch.2 in Cytokines and Chemokines in Autoimmune Disease, pp. 8-32, Plenum Publishers, 2003.
Conti et al., “IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26,”Immunology Letters88: 171-174, 2003.
Cosman, D., “The Hematopoietin Receptor Superfamily,”Cytokine5(2): 95-106, Mar. 1993.
Cunningham et al., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,”Science244: 1081-1085, Jun. 1989.
Davis et al., “Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning,”Cell87: 1161-1169, Dec. 1996.
de Groot-Kruseman et al., “Expression of the Novel Cytokine IL-21 During Acute Rejection After Clinical Heart Transplantation and the Effect of Immunosuppressive Agents,”J. Interferon&Cytokine Research22(Suppl. 1): S-97, Abstract P-2-1, 2002.
Dumoutier et al. “Human interleukin-10-related T cell-derived inducible factor: Molecular cloning and functional characterization as an hepatocyte-stimulating factor,”Proc. Natl. Acad. Sci.97(18): 10144-10149, Aug. 2000.
Dumoutier et al., “Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), a Novel Cytokine Structurally Related to IL-10 and Inducible by IL-9,”J. Immunol. 164: 1814-1819, 2000.
Dumoutier et al., “IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes,”Genes and Immunity. 1: 488-494, 2000.
Dumoutier et al., “Cloning and Characterization of IL-22 Binding Protein, a Natural Antagonist of IL-10-Related T Cell-Derived Inducible Factor/IL-22,”J. Immunol. 166: 7090-7095, 2001.
Dumoutier et al., “Cutting Edge: STAT Activation By IL-19, IL-20 and mda-7 Through IL-20 Receptor Complexes of Two Types,”J. Immunol. 167(7): 3545-3549, 2001.
Dumoutier et al., “Viral and cellular interleukin-10 (IL-10)-related cytokines: from structures to functions,”Eur. Cytokine Netw. 13(2): 5-15, Mar. 2002.
Dynan et al., “Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins,”Nature316: 774-778, Aug. 1985.
Femandez-Botran, R., “Soluble cytokine receptors: novel immunotherapeutic agents,”Exp. Opin. Invest. Drugs9(3): 497-514, 2000.
Fickenscher et al., “The interleukin-10 family of cytokines,”TRENDS in Immunology23(2): 89-96, Feb. 2002.
George et al., “Current Methods in Sequence Comparison and Analysis,” Ch. 12, inMacromolecular Sequencing&Synthesis, pp. 127-149, Alan R. Liss, Inc., 1988.
Gibbs and Pennica, “CRF2-4: isolation of cDNA clones encoding the human and mouse proteins,”Gene186: 97-101, 1997.
Gröne, “Keratinocytes and cytokines,”Veterinary Immunol. and Immunopath. 88: 1-12, 2002.
Gruenberg et al., “A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta,”Genes and Immunity2(6): 329-334, 2001.
Gurney, A., “IL-22, a novel human cytokine that signals through the Interferon receptor related proteins CRF2-4 and IL-22R,”Eur. Cytokine Network11: 39, Abstract 05002, Nov. 2000.
Harlow et al.,Antibodies: A Laboratory Manual, Ch. 5, p. 76, Cold Springs Harbor Laboratory, 1988.
He et al., “Serum Amyloid a Induces IL-8 Secretion Through A G Protein-Coupled Receptor, FPRL1/LXA4R,”J. Interferon&Cytokine Research22(Suppl. 1): S-97, Abstract P-1-23, 2002.
Henikoff et al., “Amino acid substitution matrices from protein blocks,”Proc. Natl. Acad. Sci. USA89: 10915-10919, Nov. 1992.
Holliger and Hoogenboom, “Antibodies come back from the brink,”Nature Biotech. 16: 1015-1016, 1998.
Hosoi et al., “Lipolysaccharide induces IL-20 expression in the primary cultured glial cells,&
Chandrasekher Yasmin A.
Dillon Stacey R.
Kindsvogel Wayne R.
Lehner Joyce M.
Moore Margaret Dow
Jiang Dong
Sherbina Nicholas V.
ZymoGenetics Inc.
LandOfFree
Anti-IL-22RA antibodies and binding partners and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IL-22RA antibodies and binding partners and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL-22RA antibodies and binding partners and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2671063